Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.64 |
| ▸ | MDM4 | O15151 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378040 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL1486199 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30055375 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29352428 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL378041 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30988976 | 0.93 | CASP3 (0.56) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29401049 | 0.92 | CASP3 (0.60) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29047043 | 0.91 | CASP3 (0.59) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30656568 | 0.91 | MDM4 (0.59) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29053258 | 0.91 | CASP3 (0.58) | CASP3MDM4TP53KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098519-A1 | RADIOLIGAND COMPOUNDS AND USES THEREOF | Chengdu New Radiomedicine Technology Co., Ltd. (CN) | 2026-05-15 | — | — | WO | disclosed |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-20260115333-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115334-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250154197-A1 | LIPOLYTIC PEPTIDES | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) | 2025-05-15 | — | — | US | disclosed |
| WO-2025005639-A1 | CATIONIC AMPHIPHILIC POLYPEPTIDE FOR RNA DELIVERY AND MANUFACTURING METHOD THEREOF | 인하대학교 산학협력단 | 2025-01-02 | — | — | WO | disclosed |
| EP-4482848-A2 | CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY | Purdue Research Foundation (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240424153-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2024-12-26 | — | — | US | disclosed |
| CN-119072485-A | Conjugates, compositions and methods for hydroxyapatite targeted imaging and therapy | 普渡研究基金会 | 2024-12-03 | — | — | CN | disclosed |
| US-20240382629-A1 | HETEROBIVALENT AND HOMOBIVALENT AGENTS TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA AND/OR PROSTATE-SPECIFIC MEMBRANE ANTIGEN | THE JOHNS HOPKINS UNIVERSITY | 2024-11-21 | — | — | US | disclosed |
| US-11560407-B2 | FOXP3-binding peptides and uses thereof | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2023-01-24 | — | — | US | disclosed |
| US-20220289792-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LIMITED (GB) | 2022-09-15 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-108473483-B | Compounds for medical use | 奥斯维尔医疗私人有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-14 | — | — | US | disclosed |
| US-20220184222-A1 | BICYCLE TOXIN CONJUGATES AND USES THEREOF | BICYCLETX LTD (GB) | 2022-06-16 | — | — | US | disclosed |
| CN-114364690-A | Novel radiolabeled CXCR4 targeting compounds for diagnosis and therapy | 省卫生服务机构 | 2022-04-15 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| EP-3956346-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | Provincial Health Services Authority (CA) | 2022-02-23 | — | — | EP | disclosed |
| CN-109311910-B | Tacrolimus conjugates, compositions thereof, and uses thereof | 杜兰教育基金委员会 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115334-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY | FGF23, FOLH1, HDGF | CASP3 982/4885MDM4 3501/4885TP53 621/4885 |
| US-20220184222-A1 | BICYCLE TOXIN CONJUGATES AND USES THEREOF | EPHA2, EPHB2, EPHB3 | CASP3 776/4885MDM4 4871/4885TP53 210/4885 |
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | CXCR4, CXCR1, FPR1 | CASP3 3834/4885MDM4 4011/4885TP53 2939/4885 |
| US-11560407-B2 | FOXP3-binding peptides and uses thereof | CCR3, CCR4, CXCR3 | CASP3 694/4885MDM4 1272/4885TP53 296/4885 |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | EPHA2, EPHB2, ERBB2 | CASP3 2990/4885MDM4 4213/4885TP53 135/4885 |
| US-20220289792-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | EPHA2, EPHB2, ERBB2 | CASP3 3383/4885MDM4 2761/4885TP53 147/4885 |
| US-20240424153-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY | CD44, SOST, FGF23 | CASP3 661/4885MDM4 1253/4885TP53 49/4885 |
| US-20260115333-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY | FGF23, SLC34A2, SLC34A3 | CASP3 578/4885MDM4 4565/4885TP53 663/4885 |
| US-20240382629-A1 | HETEROBIVALENT AND HOMOBIVALENT AGENTS TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA AND/OR PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FAP, FIBP, FOLH1 | CASP3 2460/4885MDM4 1681/4885TP53 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.